BCLI — Brainstorm Cell Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Brainstorm Cell Therapeutics Announces First Quarter 2026 Financial Results And Provides Corporate Update
Brief: Brainstorm Cell Therapeutics Announces $1 Million Strategic Financing At Premium To Market
Brief: Brainstorm Cell Therapeutics Announces Second Quarter Financial Results
Brainstorm Cell Therapeutics Inc expected to post a loss of 37 cents a share - Earnings Preview
Brainstorm Cell Therapeutics Inc expected to post a loss of 37 cents a share - Earnings Preview
Brief: Brainstorm Cell Therapeutics Announces Nasdaq Delisting And Transition To Otcqb
U.S. STOCKS ON THE MOVE-BTCS, BrainStorm Cell, Moderna
U.S. STOCKS ON THE MOVE- Moderna, BrainStorm Cell, General Dynamics
BrainStorm Cell up after FDA considers Citizen Petition for ALS therapy review
Brief: FDA Review Of Citizen Petition Offers A Fresh Look At NurOwn®'S Evidence Of Treatment Effectiveness
Brief: Brainstorm Cell Therapeutics Files Prospectus For Offer And Sale Of Up To 2.8 Million Shares Of Common Stock By Selling Stockholder - SEC Filing
Brief: Brainstorm Secures Key Manufacturing Partnership With Minaris For Upcoming Nurown Phase 3B Als Clinical Trials
Brainstorm Cell Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Brainstorm Cell Therapeutics Inc expected to post a loss of 97 cents a share - Earnings Preview
Brainstorm Cell Therapeutics Inc expected to post a loss of 97 cents a share - Earnings Preview
Brainstorm Cell Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Brainstorm Cell Therapeutics Inc expected to post a loss of 38 cents a share - Earnings Preview
Brief: BrainStorm Cell Therapeutics Granted Compliance Extension from Nasdaq
Brief: Brainstorm Strengthens Exosome Patent Portfolio, Receives Notice Of Allowance For U.S. Patent Covering Its Platform Technology